Northwest Biotherapeutics
NWBO
NWBO was delisted on the 16th of December, 2016.
70 hedge funds and large institutions have $78.2M invested in Northwest Biotherapeutics in 2014 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 12 reducing their positions, and 11 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 12
6.88% more ownership
Funds ownership: 13.89% → 20.77% (+6.9%)
1% less funds holding
Funds holding: 71 → 70 (-1)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
38% less call options, than puts
Call options by funds: $2.31M | Put options by funds: $3.74M
41% less capital inflows, than outflows
Capital inflows: $5.62M | Capital outflows: $9.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.17M |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
+$1.1M |
| 3 |
BlackRock Institutional Trust
San Francisco,
California
|
+$737K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$496K |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$445K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$5.16M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.18M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$888K |
| 4 |
Majedie Asset Management
London,
United Kingdom
|
-$757K |
| 5 |
TIAA CREF Investment Management
New York
|
-$390K |
NWBO Hedge Fund Activity: Q4 2014 in Review
70 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q4 2014, worth a combined $78.2M — up 80% from $43.5M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NWBO and 8 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 26 added.
The largest buyer was Goldman Sachs, adding an estimated $1.17M. The largest seller was Franklin Resources, exiting entirely with an estimated $5.16M sold.
- 70 institutional investors held Northwest Biotherapeutics (NWBO) as of Q4 2014, down from 71 in Q3 2014.
- Funds reported $78.2M of Northwest Biotherapeutics stock for Q4 2014, up 80% quarter-over-quarter.
- 8 funds opened new Northwest Biotherapeutics positions in Q4 2014 and 11 closed out, a net change of -3 holders.
- The largest Northwest Biotherapeutics buyer in Q4 2014 was Goldman Sachs, an estimated $1.17M added.
- The largest Northwest Biotherapeutics seller in Q4 2014 was Franklin Resources, an estimated $5.16M sold.
Based on aggregated 13F filings for Q4 2014.